Cortisol Secretion, Sensitivity and Activity and Hypertension
- Conditions
- HypercortisolismArterial Hypertension
- Interventions
- Diagnostic Test: Dexamethasone suppression test
- Registration Number
- NCT05766085
- Lead Sponsor
- Istituto Auxologico Italiano
- Brief Summary
The goal of this observational study is to evaluate, between patients with arterial hypertension and non hypertensive control group,
* the prevalence of hidden hypercortisolism
* the relationship between organ damage and oxidative stress level, cortisol secretion degree, sensitivity and peripheral activity
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 290
- Hypertension group: arterial hypertension
- No hypertension group: absence of arterial hypertension
- body mass index (BMI) >30 kg/m2
- active smoking (>20 cigarettes/day)
- pregnancy/lactation
- hypertension associated with family history of hypertension and cerebrovascular events before 40 years of age
- sleep apnea
- hypertension appearance in pre-pubertal age
- hypokalemia
- hypertension in the setting of an incidental adrenal mass
- classic signs and symptoms of hypercortisolism (lunar facies, striae, hypertrichosis, skin atrophy, hump)
- proven endocrine hypertension (pheochromocytoma, hyperaldosteronism, hyperparathyroidism, acromegaly, hyperthyroidism)
- renovascular hypertension
- diseases or conditions associated with increased activity of the hypothalamic-pituitary- adrenal axis and/or oxidative stress, such as type 2 diabetes, rheumatoid arthritis, severe rheumatic/autoimmune diseases, severe hematological diseases, alcoholism, depressive syndrome, chronic renal failure (GFR <45 ml/min), severe hypovitaminosis D (25OHvitaminD <10 ng/dL)
- therapies that interfere with the activity of the HPA axis (i.e. glucocorticoids, antidepressants).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description no hypertension Dexamethasone suppression test Those patients without arterial hypertension hypertension Dexamethasone suppression test Those patients suffering from arterial hypertension
- Primary Outcome Measures
Name Time Method Prevalence of hidden hypercortisolism (HidHyCo) At baseline The presence of HidHyCo will be evaluated through the determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mgDST). In case of 1mgDST \>1.8 µg/dL the patient will repeat the test and, if the result is confirmed, the patients is considered to have HidHyCo.
- Secondary Outcome Measures
Name Time Method Evaluation of glucocorticoid sensitivity At baseline In all subjects, genotyping of the N363S, BclI, ER22/23EK polymorphisms of the GR gene and of the polymorphisms will be performed
Evaluation of organ damage At baseline Organ damage will be assessed by performing echocardiography, carotid echo-doppler (arterial stiffness) and microalbuminuria evaluation, which assess hypertensive heart disease, macro-angiopathy and hypertensive nephropathy, respectively
Evaluation of glucocorticoid peripheral activity At baseline Urinary free cortisol and urinary free cortisone will be measured in all subjects; their ratio will be used as measure of glucocorticoid peripheral activity
Evaluation of oxidative stress level At baseline The determination of the degree of oxidative stress will be carried out in all patients by evaluating the enzymatic activity of dipeptidyl peptidase 3 (DPP3) in the serum
Evaluation of cortisol secretion degree At baseline The cortisol secretion will be evaluated by measuring morning plasma ACTH and serum cortisol, 24-hour urinary free cortisol, serum cortisol at 09:00 after the administration of
1 mg dexamethasone at 11 PM on the previous day
Trial Locations
- Locations (1)
Istituto Auxologico Italiano IRCCS
🇮🇹Milan, MI, Italy